BioCardia Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
BCDA$0.93+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
BIOCARDIA, INC.
Consolidated Statements of Cash Flows
(In thousands)
| Years ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating activities: | ||
| Net loss | $(11,571) | $(11,907) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 84 | 82 |
| Reduction in the carrying amount of right-of-use assets | 327 | 295 |
| Share-based compensation | 1,030 | 1,183 |
| Loss on disposal of property and equipment | 4 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 138 | (54) |
| Prepaid expenses and other current assets | 5 | 163 |
| Accounts payable | 184 | 4 |
| Accrued expenses and other current liabilities | 482 | 416 |
| Deferred revenue | (341) | (506) |
| Operating lease liability | (316) | (237) |
| Net cash used in operating activities | (9,974) | (10,561) |
| Investing activities: | ||
| Purchase of property and equipment | (12) | (70) |
| Net cash used in investing activities | (12) | (70) |
| Financing activities: | ||
| Proceeds from sales of common stock | 4,388 | 5,540 |
| Issuance costs of sale of common stock | (662) | (418) |
| Net cash provided by financing activities | 3,726 | 5,122 |
| Net change in cash and cash equivalents | (6,260) | (5,509) |
| Cash and cash equivalents at beginning of year | 7,363 | 12,872 |
| Cash and cash equivalents at end of year | $1,103 | $7,363 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Unpaid issuance costs of common stock | $195 | $172 |
| Issuance of restricted stock units in lieu of cash bonus obligations | $564 | $401 |
See accompanying notes to the consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.